qz
Hims & Hers stock jumps 14% after FDA schedules peptide compounding review

The FDA will convene an outside panel in July to weigh compounding eligibility for 7 peptides, a category Hims & Hers has been positioning to enter [...]

Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

Destination
Hims & Hers makes a big Europe push with an acquisition. Knockoff weight loss drugs could be next

Hims & Hers (HIMS) is expanding its playbook across the Atlantic — the U.S.-based telehealth company announced Tuesday that it will acquire European telehealth platform Zava. The acquisition gro [...]

Match Score: 169.58

Destination
Hims & Hers stock slipped as investors were left unimpressed with its new weight-loss drug options

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that left investors unimpressed.Read more... [...]

Match Score: 155.37

Destination
Hims & Hers stock tumbles as the FDA issues a warning about 'unapproved' weight loss drugs

Hims & Hers (HIMS), the millennial-skewed telehealth company, saw its stock tumble nearly 9% on Tuesday, as the company braces for big regulatory shifts in the weight-loss drug industry.Read more. [...]

Match Score: 137.42

Destination
Hims & Hers strikes a deal with Novo Nordisk to sell Wegovy — and the stock soars 28%

Telehealth company Hims & Hers (HIMS) announced Tuesday that it will begin selling Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy.Read more... [...]

Match Score: 118.83

Destination
The FDA rolls out its own AI to speed up clinical reviews and scientific evaluations

The FDA has launched the generative AI tool, Elsa, agency-wide to help its employees with everything from clinical reviews to investigations. Sure, we're living in a time of widespread disinforma [...]

Match Score: 77.75

Destination
Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today

Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 market — which is projected to hit $105 billion by 2030, according to Morgan S [...]

Match Score: 67.17

Destination
Hims and Hers reveal cyberattack — customer support system hacked and personal info stolen, here's what we know

At least 500 people were affected in breach at Hims and Hers. [...]

Match Score: 67.17

qz
Hims & Hers will get to sell Ozempic. Like, real Ozempic. The stock soars 50%

Novo Nordisk and Hims had clashed on and off for months as the telehealth firm marketed compounded versions of Novo's blockbuster GLP-1 drug Wegovy [...]

Match Score: 60.38

qz
Hims & Hers Advances a Consumer-Centric Digital Health Platform

HIMS is broadening its digital-first platform with Labs, hormone therapy and weight-loss programs as it scales personalized care globally. [...]

Match Score: 56.53